Preclinical Mira-55 Shows Anxiolytic Activity, No THC-like CNS Effects and IND Support
MIRA•MIRA Pharmaceuticals’ preclinical data show Mira-55 engages cannabinoid receptors without THC-like CNS side effects, producing only a modest drop in body temperature and significant anxiolytic activity. Rimonabant did not block Mira-55’s effects, indicating a distinct mechanism and supporting advancement toward an IND for chronic inflammatory pain.
1. Preclinical Study Findings
MIRA tested Mira-55 alongside THC and observed only a modest body temperature reduction, with no impact on movement or catalepsy. In anxiety models, Mira-55 significantly reduced anxiety-like behavior, a benefit not seen with THC, underscoring its differentiated behavioral profile.
2. Mechanistic Differentiation from THC
Co-administration of rimonabant fully reversed THC’s effects but failed to block Mira-55’s temperature drop, demonstrating a distinct pharmacological pathway. The unique anxiolytic response further confirms that Mira-55 does not replicate THC’s CB1-mediated liabilities.
3. IND Advancement Strategy
These integrated findings bolster MIRA’s plan to advance Mira-55 into IND-enabling studies for chronic inflammatory pain. The company highlights a large market opportunity and intends to pursue mammalian and translational work to finalize receptor activity characterization.
